Post-Operative Outcomes of Low Thermal Dissection vs. Traditional Electrosurgery

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 17, 2017

Primary Completion Date

October 24, 2018

Study Completion Date

December 3, 2018

Conditions
Breast CancerMastectomyPerfusion; ComplicationsHemostasis
Interventions
DEVICE

PlasmaBlade 3.0S

PlasmaBlade (Medtronic) is approved by United States Food and Drug Administration (FDA) as a low thermal dissection device that has shown to be associated with effective cutting, and significantly lower temperature than traditional electrosurgical dissection devices.

Trial Locations (2)

21224

Bayview Medical Center, Baltimore

21287

Johns Hopkins Hospital Outpatient Center, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medtronic

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03711916 - Post-Operative Outcomes of Low Thermal Dissection vs. Traditional Electrosurgery | Biotech Hunter | Biotech Hunter